Vivozon Pharmaceutical Co., Ltd.

KOSDAQ:A082800 Stock Report

Market Cap: ₩399.5b

Vivozon Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Vivozon Pharmaceutical has been growing earnings at an average annual rate of 17.8%, while the Semiconductor industry saw earnings growing at 8.6% annually. Revenues have been growing at an average rate of 13.2% per year.

Key information

17.8%

Earnings growth rate

26.1%

EPS growth rate

Semiconductor Industry Growth23.5%
Revenue growth rate13.2%
Return on equity-2.8%
Net Margin-3.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 40% But Its Business Is Yet to Catch Up

Dec 12
Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 40% But Its Business Is Yet to Catch Up

We Think Vivozon Pharmaceutical (KOSDAQ:082800) Is Taking Some Risk With Its Debt

Dec 02
We Think Vivozon Pharmaceutical (KOSDAQ:082800) Is Taking Some Risk With Its Debt

Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 35% But Its Business Is Yet to Catch Up

Oct 28
Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 35% But Its Business Is Yet to Catch Up

What Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) 33% Share Price Gain Is Not Telling You

Aug 02
What Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) 33% Share Price Gain Is Not Telling You

Vivozon Pharmaceutical (KOSDAQ:082800) Has A Somewhat Strained Balance Sheet

Jul 29
Vivozon Pharmaceutical (KOSDAQ:082800) Has A Somewhat Strained Balance Sheet

Some Shareholders Feeling Restless Over Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) P/S Ratio

Jun 04
Some Shareholders Feeling Restless Over Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) P/S Ratio

We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt

Mar 23
We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt

Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?

May 06
Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?

Estimating The Intrinsic Value Of Vivozon Healthcare, Inc. (KOSDAQ:082800)

Feb 18
Estimating The Intrinsic Value Of Vivozon Healthcare, Inc. (KOSDAQ:082800)

Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?

Dec 04
Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?

Revenue & Expenses Breakdown

How Vivozon Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A082800 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2487,275-2,94034,4123,524
30 Jun 2481,518-2,72529,7843,206
31 Mar 2477,515-1,98825,5262,999
31 Dec 2371,318-2,21422,6932,541
30 Sep 2363,558-15,01626,5002,734
30 Jun 2359,402-16,98426,7552,616
31 Mar 2351,411-20,94727,0852,322
31 Dec 2251,564-26,07927,7441,927
30 Sep 2252,429-65,74627,0271,777
30 Jun 2252,846-72,47229,0891,781
31 Mar 2257,175-69,52331,0963,834
31 Dec 2157,560-69,45731,6823,935
30 Sep 2156,999-47,72828,0475,721
30 Jun 2151,123-41,49221,5865,388
31 Mar 2148,923-39,36616,3863,092
31 Dec 2043,592-43,75410,8082,870
30 Sep 2040,671-30,8294,525363
31 Dec 1944,953-21,6314,931380
30 Sep 1944,701-9758,340400
30 Jun 1943,254-9,3928,583402
31 Mar 1945,740-8,3137,306368
31 Dec 1846,003-8,5347,252360

Quality Earnings: A082800 is currently unprofitable.

Growing Profit Margin: A082800 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A082800 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.

Accelerating Growth: Unable to compare A082800's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A082800 is unprofitable, making it difficult to compare its past year earnings growth to the Semiconductor industry (7.4%).


Return on Equity

High ROE: A082800 has a negative Return on Equity (-2.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 01:18
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vivozon Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mok Hyun JiMERITZ Securities Co., Ltd.
Hyun Yong KimSK Securities Co., Ltd.